The attachment of bacterial spinae.

Biofilms, bacterial signaling, and their ties to marine biology. J Ind Microbiol Biotechnol (2003) 0.97

Structural properties of the tubular appendage spinae from marine bacterium Roseobacter sp. strain YSCB. Sci Rep (2012) 0.75

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08

Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42

Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43

Cellulose biosynthesis in Acetobacter xylinum: visualization of the site of synthesis and direct measurement of the in vivo process. Proc Natl Acad Sci U S A (1976) 3.56

Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med (1987) 3.42

Controlled degradation of vaccinia virions in vitro: an electron microscopic study. J Ultrastruct Res (1966) 2.66

A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48

Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26

Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol (1988) 2.22

Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med (1991) 2.04

Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science (1992) 2.01

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS (1999) 1.70

Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol (1998) 1.60

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis (1995) 1.57

Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis (1991) 1.57

Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS (2000) 1.54

A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS (2001) 1.45

Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis (1988) 1.44

Genetic evaluation of suspected cases of transient HIV-1 infection of infants. Science (1998) 1.43

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med (1993) 1.42

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS (1998) 1.40

Cell wall structure and deposition in Glaucocystis. J Cell Biol (1978) 1.35

The effect of light on the antibacterial activity of beta-thujaplicin. Can J Microbiol (1973) 1.32

Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol (1995) 1.27

Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS (2000) 1.27

Indeterminate human immunodeficiency virus type 1 western blots: seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation. J Infect Dis (1991) 1.24

Markers of HIV infection prior to IgG antibody seropositivity. JAMA (1989) 1.24

Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis (1998) 1.23

Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis (1997) 1.22

Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. Arch Intern Med (1994) 1.22

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20

Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system. J Clin Invest (1992) 1.20

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med (2001) 1.18

Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis (1995) 1.16

Vasectomy and human immunodeficiency virus type 1 in semen. J Urol (1998) 1.13

Risk factors for HIV-1 shedding in semen. Am J Epidemiol (1999) 1.12

The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis (1994) 1.10

Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther (1992) 1.09

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis (1996) 1.07

Two bacteriophages of Clostridium difficile. J Clin Microbiol (1985) 1.07

Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology (2011) 1.07

Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2000) 1.05

Fraction 1 protein crystals in chloroplasts of isolated tobacco leaf protoplasts: a thin-section and freeze-etch morphological study. J Ultrastruct Res (1976) 1.05

The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res Hum Retroviruses (1999) 1.04

Antibacterial activity of beta-thujaplicin. Can J Microbiol (1973) 1.04

Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis (1995) 1.04

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis (2000) 1.04

Intracellular development of a bacteriophage of Clostridium perfringens. Can J Microbiol (1970) 1.03

Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.02

Arrangement of morphological subunits in bacterial spinae. Can J Microbiol (1976) 1.02

Transmission of genital herpes by donor insemination. JAMA (1989) 1.01

HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.99

Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma. J Clin Microbiol (2000) 0.98

Crystalline aggregates observed in the vicinity of freeze-etched poxvirus inclusions. Can J Microbiol (1972) 0.98

Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma. J Infect Dis (1997) 0.97

Cytokine activation of human macrophages infected with HIV-1 to inhibit intracellular protozoa. J Acquir Immune Defic Syndr (1992) 0.96

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol (1999) 0.96

Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology (1993) 0.96

Altered nuclear pore diameters in G1-arrested cells of the yeast Saccharomyces cerevisiae. J Bacteriol (1978) 0.95

The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr (1999) 0.94

Seminal shedding of human immunodeficiency virus type 1 and human cytomegalovirus: evidence for different immunologic controls. J Infect Dis (1995) 0.92

A freeze-etch study of the effects of extracellular freezing on cellular membranes of wheat. Planta (1985) 0.90

Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.90

Liver necrosis, adenovirus type 2 and thymic dysplasia. Virchows Arch A Pathol Pathol Anat (1973) 0.90

Comparison of assays to detect cytomegalovirus shedding in the semen of HIV-infected men. J Virol Methods (2000) 0.89

Interactions at the surface of plant cell protoplasts; an electrophoretic and freeze-etch study. J Bioenerg (1973) 0.89

Effects of clinical stage and immunological status on semen analysis results in human immunodeficiency virus type 1-seropositive men. Andrologia (1998) 0.88

Spinin: the subunit protein of bacterial spinae. Can J Microbiol (1976) 0.86

Self-assembly of bacteriophage lambda tails. Can J Microbiol (1971) 0.86

Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res (1996) 0.85

Structure of microtubules: a study of freeze-etched and negatively stained microtubules from the ovaries of Notonecta. Z Zellforsch Mikrosk Anat (1973) 0.85

Trichinosis with ventilatory failure and persistent myocarditis. Clin Infect Dis (1993) 0.85

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis (1994) 0.84

Bodies of wall-like material ("wall-bodies") produced intracellularly by cultured isolated protoplasts and plasmolysed cells of higher plants. Protoplasma (1974) 0.83

The arrangement of subunits in the shell of ferritin. Electron microscopic observations of molecules negatively stained with uranyl acetate. J Ultrastruct Res (1970) 0.83

Morphology of deoxyribonucleic acid extracted from cores of vaccinia virus. J Virol (1967) 0.83

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med (1998) 0.83

"Large" and "small" nuclear pore complexes; the influence of glutaraldehyde. J Microsc (1977) 0.82

A mutant of its multiplication in three cell types. Virology (1965) 0.82

Interferon inhibition of autogenously induced virions (C particles) in synchronized L-929 cell cultures. J Natl Cancer Inst (1974) 0.82

A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group). AIDS Res Hum Retroviruses (1992) 0.82

Fertility parameters in men infected with human immunodeficiency virus. J Infect Dis (1991) 0.81

Progression of human immunodeficiency virus type-1 infection after allogeneic marrow transplantation. Am J Med (1990) 0.81

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis (1999) 0.81

A mechanism for the pinocytosis of latex spheres by tomato fruit protoplasts. J Bioenerg (1971) 0.80

Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis (2000) 0.80

Wheat tissues freeze-etched during exposure to extracellular freezing: distribution of ice. Planta (1985) 0.80

Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.79

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol (1991) 0.78

Cognitive risk factors and neuropsychological performance in HIV infection. Int J Neurosci (1993) 0.78

The natural history of HIV infection: implications for the assessment of antiretroviral therapy. Clin Infect Dis (1993) 0.78

Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1996) 0.77